|
Profile
|
Delegates :
Tamio Mizukami, Ph.D. |
|
Incorporated :
April 3 , 2006 |
Paid in Capital :
92 Million yen |
Employees :
5 members |
Address :
Tamura-cho 1281-8 Nagahama Bioincubation Center, Nagahama-si SHIGA
〒526-0829
|
TEL/FAX :
/ |
URL：
https://www.frontierpharma.net/english-home/ |
Attachment :
 Frontier_Pharma_Corporate_Profile_20260608.pdf [ 2MiB ] |
Mission/Background :
Frontier Pharma is a cell-quality-management infrastructure company that enhances cell evaluation in regenerative medicine, cell manufacturing, and drug-discovery support through its Cell Visualization Technology based on label-free AI image analysis. From ordinary microscope and bright-field images, we non-invasively and longitudinally estimate and visualize cell number, confluency, morphological features, and function-related information such as mitochondrial membrane potential. Our technology supports in-process quality evaluation, culture monitoring, early awareness of potential quality changes, and manufacturing decision support. Applicable to iPS cells, MSCs, organoids, and spheroids, it promotes standardization toward QbD/PAT and GMP/GCTP. We aim to transform cell evaluation from expert-dependent visual assessment into data-driven quality management for regenerative-medicine products, drug screening, pharmacology/toxicity studies, and CPC/CDMO operations. |
|
Technology & Business
|
Cell Visualization Technology is an AI image-analysis technology that uses ordinary microscope and bright-field images to non-invasively and longitudinally estimate, visualize, and quantify cell number, confluency, morphological features, and function-related information such as mitochondrial membrane potential. In iPS-cell and MSC culture processes, it supports morphological PAT by helping monitor culture status, quality scores, and potential deviations, and functional PAT by validating information correlated with fluorescence assays such as JC-1 as candidate indicators. In drug discovery, it is being applied to label-free, non-destructive screening, pharmacology, and toxicity evaluation using organoids, spheroids, and disease-model cells. The AI is designed as a fixed, deterministic model with managed intended use, input conditions, version control, independent validation, and human-in-the-loop review. Final decisions remain under the customer's QA system.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
MSC in-process quality evaluation system
|
Launched
|
Estimates cell number, confluency, and morphological quality from label-free images to support decisions.
|
Expand adoption and joint validation with MSC manufacturers and research institutions.
|
iPS cell non-invasive counting AI
|
Launched
|
Estimates nuclear positions from transmitted-light images to quantify cells in dense colonies.
|
Expand implementation in iPS manufacturing and define applicable imaging conditions.
|
MitoMetrica: visualization of membrane-potential-related information
|
Discovery
|
Visualizes membrane-potential information correlated with JC-1 assessment from bright-field images.
|
Validate candidate indicators under Go-Tech and support differentiation-potential prediction.
|
ImageneStem: stem-cell quality evaluation support platform
|
Discovery
|
Integrates cell number, morphology, and function-related information with version control and HITL.
|
Implement stepwise as a decision-support system toward GMP/GCTP.
|
General-purpose MSC model and AI super-resolution technology
|
Preclinical
|
Supports feature extraction using a 36-MSC-line model and AI super-resolution.
|
Define acceptance criteria by cell origin and imaging condition; expand applicability.
|
|
Highlights
|
Our core patent for deriving cell-position information from label-free images is granted in Japan, the US, Europe, and China. Our iPS quality-evaluation technology was selected for METI Go-Tech (FY2024-2026). We are advancing MitoMetrica visualization of membrane-potential-related information, and confirmed non-invasive iPS counting (Pearson 0.83; 98.5% agreement) and a 36-MSC-line model within +/-10%, advancing in-process quality evaluation for regenerative medicine and cell manufacturing.
|
|
Alliance strategy
|
We seek joint research, PoC, and implementation partners to visualize and quantify cell number, confluency, morphology, and function-related information in-process using label-free AI image analysis. We welcome regenerative-medicine developers, CPCs/CDMOs, pharmaceutical companies, equipment, microscope, media and consumables manufacturers, and academic institutions to standardize cell manufacturing, quality control, and drug-discovery evaluation, including ImageneStem and MitoMetrica co-development.
|
|
|